NCT03004248View on ClinicalTrials.gov

Safety of Single and Repeat Treatments of DaxibotulinumtoxinA for Injection for Treatment of Moderate to Severe Glabellar Lines

PHASE3CompletedINTERVENTIONAL
Enrollment

2,691

Participants

Timeline

Start Date

December 9, 2016

Primary Completion Date

October 17, 2018

Study Completion Date

October 17, 2018

Conditions
Glabellar Frown Lines
Interventions
BIOLOGICAL

Botulinum Toxins, Type A

Intramuscular Injection

Trial Locations (61)

10011

New York

10016

New York

10022

New York

10028

New York

10029

New York

10075

New York

10604

White Plains

11795

West Islip

19026

Drexel Hill

20007

Washington D.C.

20037

Washington D.C.

20769

Glenn Dale

20850

Rockville

21030

Hunt Valley

21208

Baltimore

27262

High Point

27517

Chestnut Hill

Chapel Hill

28207

Charlotte

33137

Miami

33146

Coral Gables

33401

West Palm Beach

33431

Boca Raton

34209

Bradenton

35205

Birmingham

37203

Nashville

37215

Nashville

48009

Birmingham

53092

Mequon

55432

Fridley

60069

Lincolnshire

60563

Naperville

60611

Chicago

63122

St Louis

68144

Omaha

70124

New Orleans

70130

New Orleans

77056

Houston

77494

Katy

77845

College Station

78746

Austin

80111

Greenwood Village

90069

Los Angeles

90210

Beverly Hills

90266

Manhattan Beach

90404

Santa Monica

92024

Encinitas

92121

San Diego

92122

San Diego

92663

Newport Beach

94117

San Francisco

94538

Fremont

95661

Roseville

95819

Sacramento

97223

Portland

07042

Montclair

V5Z 4E1

Vancouver

L7N 3N2

Burlington

M5R3N8

Toronto

L4L 8E2

Woodbridge

H3Z 1BZ

Montreal

All Listed Sponsors
lead

Revance Therapeutics, Inc.

INDUSTRY

NCT03004248 - Safety of Single and Repeat Treatments of DaxibotulinumtoxinA for Injection for Treatment of Moderate to Severe Glabellar Lines | Biotech Hunter | Biotech Hunter